Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses some of the most interesting abstracts presented at the recent ASH 2022 congress that show advances in triplet therapy for relapsed or refractory acute myeloid leukaemia.
Abstracts discussed:
Abstract 61: ‘Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML‘ (00:10-01:35)
Abstract 62: ‘Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)‘ (01:35-02:30)
Abstract 218: ‘FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial‘ (02:30-02:54)
Abstract 222: ‘Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia‘ (02:50-03:50)
Disclosures: Jorge Cortes is a consultant for Novartis, Pfizer, Takeda, Sun Pharma and Rigel. He has received grant/research support from Novartis and Sun Pharma, and is on the advisory board for Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 64th ASH Annual Meeting & Exposition
Access more Leukaemia content here
